Serologicals' Upstate Group Announces Winner of 2006 Young Cell Signaller Award; Rashu Bhargava Seth Receives Award at the Thir
2006年6月22日 - 12:01AM
ビジネスワイヤ(英語)
Serologicals Corporation (NASDAQ: SERO) today announced that Rashu
Bhargava Seth, from the University of Texas Southwestern Medical
Center at Dallas, has been named the 2006 Young Cell Signaller. She
was chosen from among five finalists and more than 86 entries in
its Upstate 2006 Young Cell Signaller Award competition at the
Third Annual Cell Signalling Symposium. Seth's presentation was
entitled "Understanding Host Antiviral Signaling Pathways." Entries
were submitted as abstracts by Ph.D. students and first time
post-doctorates competing to win $17,000 worth of support funding
for their laboratory, a personal cash prize of $8,500 and a trophy.
The finalists presented their work during the recent Cell
Signalling Symposium held in Dundee, Scotland (U.K.), and were
judged by symposium attendees and an experienced scientific panel
including two of the world's most cited scientists, Sir Philip
Cohen and Professor Dario Alessi. Each entrant gave a 25-30 minute
presentation, followed by a five-minute question and answer period.
"The 3rd Annual Cell Signalling Symposium attracted some of the
best researchers in the field of innate and adaptive immune system.
The calibre of research presentations and discussions at the
symposium was outstanding," said Seth. "The Upstate Young Cell
Signaller competition provides an excellent platform for students
and post-docs to present their work. The ideas and suggestions I
got for my work will really help me with my project. It is an
honour and big encouragement for me to receive this award. The cash
award for my laboratory will be used to buy reagents for my
project." The four other finalists and their presentations were:
Marzena Bienko, from the John Wolfgang Goethe University,
Frankfurt, presenting "Novel Ubiquitin-Binding Domains in Y-Family
Polymerases Regulate Translesion Synthesis." Kate Jeffrey, from the
Garvan Institute of Medical Research, presenting "PAC-1
Phosphatase: as key positive regulator of immune cell function and
inflammatory responses." Nina Jones, from the Samuel Lunenfeld
Research Institute, presenting "Nck Adaptors Link Nephrin to the
Actin Cytoskeleton of Kidney Podocytes." Omar Perez, from the
Stanford University School of Medicine, presenting "Activation
State Analysis in Single Cells: a systems biology approach to
understanding intracellular mechanisms." Serologicals Corporation
President and CEO David Dodd commented on the finalists, "These
young people represent the future of our industry in medical
research. I congratulate all of them and wish them the best in
their future work." The Third Annual Cell Signalling Symposium was
held June 11-14, 2006, at the Apex City Quay Hotel, Dundee, U.K. It
was co-sponsored by Upstate and the MRC Protein Phosphorylation
Unit at the University of Dundee. The focus for the three day,
not-for-profit meeting was 'Signalling in the Innate and Adaptive
Immune Systems'. Upstate is a leading research discovery provider
of the highest quality cell signaling products and services to the
life science market. Its customers are biomedical researchers at
drug discovery companies and academic institutions in the key
disciplines of oncology, immunology, proteomics, cardiology and
neurology. Known for its enabling, innovative solutions to help
understand the biology of kinases, chromatin, g-proteins and
cytokines, Upstate's advanced cell biology tools - drug screening
services, enzymes, state specific antibodies, siRNA kits and
multiplex assays - are used by thousands of customers worldwide,
everyday, to accelerate human health. Upstate, a Serologicals
company, is headquartered in Temecula, California, and offices in
Dundee, Scotland. For more information, please visit our website
www.upstate.com. Serologicals Corporation (NASDAQ: SERO),
headquartered in Atlanta, Georgia, is a global provider of
biological products and enabling technologies, which are essential
for the research, development and manufacturing of biologically
based life science products. The Company's products and
technologies are used in a wide variety of innovative applications
within the areas of oncology, hematology, immunology, cardiology
and infectious diseases, as well as in the study of molecular
biology. Serologicals has approximately 1,000 employees worldwide,
and its shares are traded on the NASDAQ national stock market under
the symbol SERO. On April 25, 2006, Serologicals entered into an
Agreement and Plan of Merger with Millipore Corporation and one of
its wholly-owned subsidiaries, pursuant to which Millipore
Corporation will acquire Serologicals. For more information, please
visit our website: www.serologicals.com. Serologicals is a
registered trademark of Serologicals Royalty Company.
Serologicals (NASDAQ:SERO)
過去 株価チャート
から 5 2024 まで 6 2024
Serologicals (NASDAQ:SERO)
過去 株価チャート
から 6 2023 まで 6 2024